| Literature DB >> 32104457 |
Mei Lu1, Qiujun Qiu1, Xiang Luo1, Xinrong Liu1, Jing Sun1, Cunyang Wang2, Xiangyun Lin1, Yihui Deng1, Yanzhi Song1.
Abstract
Although active constituents extracted from plants show robust in vitro pharmacological effects, low in vivo absorption greatly limits the widespread application of these compounds. A strategy of using phyto-phospholipid complexes represents a promising approach to increase the oral bioavailability of active constituents, which is consist of ''label-friendly" phospholipids and active constituents. Hydrogen bond interactions between active constituents and phospholipids enable phospholipid complexes as an integral part. This review provides an update on four important issues related to phyto-phospholipid complexes: active constituents, phospholipids, solvents, and stoichiometric ratios. We also discuss recent progress in research on the preparation, characterization, structural verification, and increased bioavailability of phyto-phospholipid complexes.Entities:
Keywords: Active constituents; Bioavailability; Hydrogen bonds; Phyto-phospholipid complexes
Year: 2018 PMID: 32104457 PMCID: PMC7032241 DOI: 10.1016/j.ajps.2018.05.011
Source DB: PubMed Journal: Asian J Pharm Sci ISSN: 1818-0876 Impact factor: 6.598
Fig. 1Structure of phyto-phospholipid complexes and liposomes.
Fig. 2Structure of phosphatidylcholine (PC).
Fig. 3Structure of selected polyphenols: (a) EGCG, (b) Hesperidin, (c) Curcumin, and (d) Rutin.
Fig. 4Structure of (a) 25-OCH3-PPD, (b) EVO, and (c) SRM.
Therapeutic applications of different phyto-phospholipid complexes on the market [33], [34], [35], [36], [37].
| S. no. | Trade name | Phytoconstituents complex | Indication |
|---|---|---|---|
| 1. | Epigallocatechin 3-O-gallate from | Systemic antioxidant. Protect against cancer and damage to cholesterol. | |
| 2. | Ginkgo flavono glycosides from | Protects brain and vascular lining. | |
| 3. | Silybin phytosome | Silybin from silymarin | Provides antioxidant protection for the liver and skin. |
| 4. | Glycyrrhiza phytosome | 18-beta glycyrrhetinic acid | Anti-inflammatory activity |
| 5. | Grape seed (Leucoselect) phytosome | Procyanidins from vitis Vinifera | Anti-oxidant, anticancer |
| 6. | Curcumin (Merinoselect) phytosomes | Polyphenol from Curcuma Longa | Cancer chemo preventive agent improving the oral bioavailability of curcuminoids, and the plasma. |
| 7. | Polyphenols from olive oil | Inhibit harmful oxidation of LDL cholesterol, and provides an anti-inflammatory effect. | |
| 8. | An extract of saw palmet to berries through supercritical CO2 (carbondioxide) extraction | It is beneficial to the normal functioning of the prostate | |
| 9. | PA2 phytosome horse Chestnut bark | Proanthocyanidin A2 from | Anti-wrinkles, UV protectant |
| 10. | Zanthalene phytosome | Zanthalene from zanthoxylum bungeanum | Soothing, anti-irritant, anti-itching |
| 11. | Centella phytosome | Terpenes | Vein and skin disorders |
| 12. | Hawthorn phytosomeTM | Flavonoids from | Nutraceutical, cardio‐protective and antihypertensive |
Fig. 5A 3D conformational model of 20(S)-protopanaxadiol and phospholipids after docking and optimization. (a) 20(S)-protopanaxadiol and phospholipids with an interpolated charge surface; (b) hydrogen bond interactions between the molecules (reproduced with permission from [47]). Copyright 2016 MDPI.
Major pharmacokinetic parameters [19], [30], [42], [49]–52].
| Parameter | AUC(0–24 h)(ng/h/ml) | Ref. | ||
|---|---|---|---|---|
| 25-OCH3-PPD | 2.25 ± 2.47 | 7.18 ± 3.39 | 26.65 ± 7.11 | |
| 25-OCH3-PPD-phospholipid complexes | 2.10 ± 0.55 | 28.07 ± 19.52 | 97.24 ± 40.17 | |
| Quercetin (103) | 0.50 ± 0.07 | 0.67 ± 0.08 | 2.04 ± 0.38 | |
| Quercetin-phospholipid complexes (103) | 0.75 ± 0.10 | 1.58 ± 0.11 | 8.12 ± 0.95 | |
| Quercetin | 1.21 | 179.21 | 1368.26 | |
| Quercetin-phospholipid complexes | 1.02 | 724.89 | 3321.05 | |
| Kaempferol | 6.32 | 180.23 | 1139.59 | |
| Kaempferol-phospholipid complexes | 5.83 | 323.56 | 2228.21 | |
| Isorhamnetin | 7.21 | 195.96 | 1153.66 | |
| Isorhamnetin-phospholipid complexes | 4.32 | 672.29 | 2722.37 | |
| Luteolin | 2.5 ± 0.75 | 3410 ± 910 | 10,420 ± 2350 | |
| luteolin–phospholipid complexes | 2 ± 0.63 | 9770 ± 1250 | 55,790 ± 5760 | |
| Berberine | 0.5 | 66.01 ± 15.03 | 384.45 ± 108.62 | |
| berberine-phospholipid complexes | 2 | 219.67 ± 6.02 | 1169.19 ± 93.75 | |
| Oleanolic acid (OA) | 0.313 ± 0.12 | 59.5 ± 10.64 | 259.6 ± 22.98 | |
| Solidified OA-phospholipid complexes | 0.46 ± 0.001 | 78.7 ± 10.18 | 360.6 ± 19.13 | |
| Rosuvastatin | 1.94 ± 0.89 | 183.95*103± 4.56*103 | 671.56*103± 5.64*103 | |
| Rosuvastatin–phospholipid complexes | 1.41 ± 0.95 | 674.17*103± 1.24*103 | 2018.59*103± 3.79*103 |
Fig. 6Schematic of the preparation of phyto-phospholipid complexes.